VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma.

Maurizio MartiniIvana de PascalisQuintino Giorgio D'AlessandrisVincenzo FiorentinoFrancesco PiercontiHany El-Sayed MareiLucia Ricci-VitianiRoberto PalliniLuigi Maria Larocca

Published in: BMC cancer (2018)

Quantitative analysis of VEGF-121 isoform in the plasma of patients with recurrent GB could be a promising predictor of response to anti-angiogenetic treatment.

Keyphrases

vascular endothelial growth factor
endothelial cells
stem cells
bone marrow